5:53 PM
 | 
Nov 07, 2013
 |  BC Extra  |  Clinical News

Agenus' HerpV meets in Phase II genital herpes trial

Agenus Inc. (NASDAQ:AGEN) said three injections of HerpV given two weeks apart met the primary endpoint in the Phase II C-400-02 trial to treat genital herpes caused by herpes simplex virus type 2 (HSV-2) infection. HerpV reduced viral shedding at day 45...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >